Liquidia Shares Plunge 25% After Delaware Court Backs United Therapeutics Patent

1 articles · Updated · CNBC · Sep 30

Liquidia sank about 25% before trading was halted after a U.S. District Court in Delaware found the company infringed a United Therapeutics patent.
The court also denied Liquidia's motion to strike United Therapeutics' challenge to the prior-art status of another patent, deepening the legal setback.
United Therapeutics shares jumped 15% on the ruling, signaling investors expect the decision to strengthen its position in the patent dispute.

Sources

Left100%

After the Delaware patent ruling, how much of Liquidia’s collapse and United Therapeutics’ surge reflects lasting fundamental change?

Why did Rogers jump while Jabil fell, even though both delivered upbeat numbers and guidance?

Is FormFactor’s rally a sign that AI’s biggest winners may be hidden in chip testing, not chipmaking?

1 total

Left100%